Malignant Neoplasm of Stomach Completed Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Gastric Cancers / Stomach Cancer / Gastric cancer / Gastric Malignancies / Gastric cancer NOS / Cancer of Stomach / Malignant neoplasm of stomach, unspecified / Gastric malignancy

IndicationStatusPhase
DBCOND0045917 (Malignant Neoplasm of Stomach)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00394433Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric CancerTreatment
NCT00217581Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction CancerTreatment
NCT00137813Avastin and Taxotere for Esophagogastric CancerTreatment
NCT00673673FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric CancerTreatment
NCT00737438Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ AdenocarcinomaTreatment